SEC Form 4 · accession 0001237899-16-000078
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
P Roy Vagelos
Officer — Chairman of the Board · Director
Period of report
May 12, 2016
Accepted (ET)
May 13, 2016 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 12, 2016 | M | 230,684 | $20.32 | A | 563,564 | D | |
| Common Stock | May 12, 2016 | F | 12,713 | $368.70 | D | 550,851 | D | |
| Common Stock | May 12, 2016 | F | 112,020 | $368.70 | D | 438,831 | D | |
| Common Stock | Jan 4, 2016 | G | 387 | $0.00 | D | 153,548 | I | by CLAT |
| Common Stock | Apr 1, 2016 | G | 584 | $0.00 | D | 152,964 | I | by CLAT |
| Common Stock | holding | — | — | — | 2,290 | I | By 401(k) Plan | |
| Common Stock | holding | — | — | — | 92,947 | I | by Spouse as Trustee | |
| Common StockF1 | holding | — | — | — | 1,203 | I | by trust for grandch |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $20.32 | May 12, 2016 | M | 230,684 | D | — | Dec 18, 2016 | Common Stock | 230,684 | 76,895 | D |
Explanation of responses
- F1By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
- F2The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.